The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II dose optimization update with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma or endometrial carcinoma.
 
Linda Duska
Consulting or Advisory Role - Ellipses Pharma (Inst); Inovio Pharmaceuticals; Merck (Inst); Regeneron
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Cerulean Pharma (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Millennium (Inst); Morab (Inst); Morphotek (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst); Syndax (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Editor, British Journal of Ob/Gyn; UpToDate
 
Kalyan Banda
Honoraria - GlaxoSmithKline; Immunogen
Research Funding - Kineta (Inst); Lilly (Inst); MorphoSys (Inst); Pfizer (Inst); Regeneron (Inst)
 
Ana Oaknin
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Debiopharm Group; Deciphera; Eisai; Exelixis; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Merck Sharp & Dohme; Mersana; Myriad Genetics; Novocure; OncoXerna Therapeutics; PharmaMar; Regeneron; Roche; Seagen / Pfizer; Shattuck Labs; Sutro Biopharma; TORL Therapuetics; Zentalis; Zymeworks
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Immunogen; MSD; Roche
Research Funding - Abbvie (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche
 
Vincent Ribrag
Employment - PEGASCY
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Abbvie; BeiGene; Ipsen
Research Funding - Astex Pharmaceuticals; GlaxoSmithKline
Travel, Accommodations, Expenses - AstraZeneca
 
Antonio Gonzalez Martin
Consulting or Advisory Role - Abbvie; Alkermes; Amgen; AstraZeneca; BioNTech SE; Clovis Oncology; Daiichi Sankyo; Eisai; Genmab; Hedera Dx; Immunogen; Incyte; Kartos Therapeutics; Macrogenics; Mersana; MSD; Novartis; Novocure; Oncoinvent; Pfizer/EMD Serono; Pharma&; Regeneron; Roche; Seagen; SOTIO; Sutro Biopharma; Takeda; Tesaro/GSK; Torl Biotherapeutics; Tubulis GmbH
Speakers' Bureau - AstraZeneca; Clovis Oncology; MSD Oncology; PHARMA&; PharmaMar; Roche; Tesaro/GSK
Research Funding - Roche (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; PharmaMar; Roche; Tesaro/GSK
 
Nehal Lakhani
Research Funding - Alexo Therapeutics (Inst); Alkermes (Inst); Alkermes/Mural Oncology (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Arcus Ventures (Inst); Artios (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech SE (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Janssen (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
 
Jung-Yun Lee
Honoraria - AstraZeneca; Genmab; Merck Serono; MSD; Regeneron; Seagen
Consulting or Advisory Role - Abbvie (Inst); Advenchen Laboratories (Inst); Alkermes (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); bms (Inst); CanariaBio (Inst); Cellid (Inst); CKD pharm (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); genemedicine (Inst); Genmab (Inst); GI Innovation (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Janssen Oncology (Inst); Kelun (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD; Novartis (Inst); onconic therapeutics (Inst); Ono Pharmaceutical (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Sutro Biopharma (Inst); Synthon (Inst); Takeda (Inst); Torl Biotherapeutics (Inst); Zymeworks (Inst)
Speakers' Bureau - AstraZeneca; Eisai; MSD; Roche; Takeda
Research Funding - Ascendis Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Janssen Oncology (Inst); Merck (Inst); Mersana (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); OncoQuest Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst); Takeda (Inst)
 
Alok Tewari
Stock and Other Ownership Interests - B.A.I. Biosciences; Inflammatix; Moderna Therapeutics; Teladoc
 
Susana Banerjee
Stock and Other Ownership Interests - Innotive Diagnostics; Perci Health
Honoraria - Abbvie; AstraZeneca; Eisai; GlaxoSmithKline; Immunogen; MSD Oncology; Pharmaand; Verastem
Consulting or Advisory Role - Abbvie; Astrazeneca; Biogene; BioNTech SE; Eisai; Genmab; Gilead Sciences; GlaxoSmithKline; Grey Wolf Therapeutics; Immunogen; Incyte; ITM Oncologics; Lilly; MSD Oncology; Myriad Genetics; Seagen; Torl Biotherapeutics; Verastem; Zymeworks
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Verastem; Zymeworks
(OPTIONAL) Uncompensated Relationships - International Cancer Foundation; Royal Society of Medicine President Oncology Session
 
Maria-Pilar Barretina-Ginesta
Consulting or Advisory Role - Abbvie; AstraZeneca; Clovis Oncology; Eisai Europe; GlaxoSmithKline; MSD Oncology; Pharma&; PharmaMar; Regeneron
Speakers' Bureau - Abbvie; AstraZeneca Spain; Eisai Europe; GlaxoSmithKline; MSD Oncology; Regeneron
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD Oncology
 
Valentina Boni
Employment - Next Oncology; Next Oncology; Quironsalud
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - 1TRIALSP
Honoraria - Amunix; EMD Serono/Merck; Guidepoint Global; IDEAYA Biosciences; Janssen Oncology; Loxo; MSD Oncology; Puma Biotechnology
Consulting or Advisory Role - EMD Serono/Merck; Guidepoint Global; Janssen Research & Development; Lilly; Lilly; Nanobiotix; Novartis; OncoArt
Speakers' Bureau - Lilly; MSD; Solti; TACTICS; TACTICS
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Bayer; START
 
Mehdi Brahmi
Honoraria - Amgen; PharmaMar
Consulting or Advisory Role - Deciphera; SpringWorks Therapeutics
Expert Testimony - Bayer; Bayer; Deciphera
Travel, Accommodations, Expenses - mundipharma; PharmaMar
 
Lauriane Eberst
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD
 
Jae Hoon Kim
No Relationships to Disclose
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - AstraZeneca; BioNTech; Clovis Oncology; Eisai; Gilead Sciences; GlaxoSmithKline; Immunogen; Incyte; mersana; MSD Oncology; Novocure; Nuvation Bio; OCXERNA; Pieris Pharmaceuticals; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novocure; Nuvation Bio; OCXERNA; Pieris Pharmaceuticals; Roche/Genentech
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; MSD Oncology
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Corcept Therapeutics; GlaxoSmithKline
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo/Lilly; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Novocure; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; ImmunoGen; MSD; Seagen
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Pharma& (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Menarini
(OPTIONAL) Uncompensated Relationships - ENGOT; Gynecological Cancer InterGroup; MITO
 
Nicola Faulhaber
Employment - MorphoSys GmbH
 
Lennart Kann
Employment - MorphoSys GmbH
Stock and Other Ownership Interests - MorphoSys
 
Anjali Thakur
Employment - MorphoSys GmbH
 
Charles Drescher
No Relationships to Disclose